

## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

**SECTION 1: IDENTIFICATION** 

Product name : Insulin Glargine Formulation

Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd

Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Skin corrosion/irritation : Category 2

Serious eye damage/eye irri-

tation

Category 1

Specific target organ toxicity - :

repeated exposure (Oral)

Category 2 (Blood, Nervous system)

**GHS** label elements

Hazard pictograms :

Signal word : Danger

Hazard statements : H315 Causes skin irritation.

H318 Causes serious eye damage.

H373 May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

Precautionary statements : Prevention:

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

P280 Wear protective gloves/ eye protection/ face protection.

#### Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P314 Get medical advice/ attention if you feel unwell.

P332 + P313 If skin irritation occurs: Get medical advice/ atten-

tion.

P362 + P364 Take off contaminated clothing and wash it before

reuse.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

#### Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Insulin Glargine	160337-95-1	>= 60 -<= 100
m-Cresol	108-39-4	>= 3 -< 5

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn. Get medical attention immediately.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

Most important symptoms and effects, both acute and

delayed

: Causes skin irritation.

Causes serious eye damage.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection.

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are re-



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

leased into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage : Keep in properly labelled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Insulin Glargine	160337-95-1	TWA	3 μg/m3 (OEB 4)	Internal
m-Cresol	108-39-4	TWA	5 ppm 22 mg/m3	AU OEL



## **Insulin Glargine Formulation**

Version Date of last issue: 30.09.2023 Revision Date: SDS Number: 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

Further information: Skin absorption			
TWA (Inhal-	20 mg/m3	ACGIH	
able fraction			
and vapor)			

**Engineering measures** Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Combined particulates and organic vapour type

Filter type Hand protection

Material Chemical-resistant gloves

Choose gloves to protect hands against chemicals depending Remarks

> on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Wear the following personal protective equipment: Eye protection

Chemical resistant goggles must be worn.

If splashes are likely to occur, wear:

Face-shield

Skin and body protection Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Crystalline powder **Appearance** 

Colour white

Odour No data available

Odour Threshold No data available

pН No data available



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

**Components:** 

**Insulin Glargine:** 

Acute oral toxicity : Remarks: No data available

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

m-Cresol:

Acute oral toxicity : LD50 (Rat): 121 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Acute dermal toxicity : LD50 (Rabbit): 301 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes skin irritation.

Components:

**Insulin Glargine:** 



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

Remarks : No data available

m-Cresol:

Species : Rabbit

Result : Corrosive after 3 minutes to 1 hour of exposure

Serious eye damage/eye irritation

Causes serious eye damage.

**Components:** 

**Insulin Glargine:** 

Remarks : No data available

m-Cresol:

Species : Rabbit

Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Insulin Glargine:

Remarks : No data available

**Chronic toxicity** 

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

**Insulin Glargine:** 

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

m-Cresol:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Ingestion Method: OECD Test Guideline 475

Result: negative

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

### **Insulin Glargine:**

Species : Rat Exposure time : 2 Years

NOAEL : 0.455 mg/kg body weight

Result : negative

Species : Mouse Exposure time : 2 Years

NOAEL : 0.455 mg/kg body weight

Result : negative

m-Cresol:

Species : Mouse, males
Application Route : Ingestion
Exposure time : 105 weeks
Result : equivocal

Remarks : Based on data from similar materials

Species : Mouse, female
Application Route : Ingestion
Exposure time : 106 - 107 weeks

Result : positive

Remarks : Based on data from similar materials

Carcinogenicity - Assess-

: Weight of evidence does not support classification as a car-

ment

## cinogen

## Reproductive toxicity

Not classified based on available information.



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

### **Components:**

**Insulin Glargine:** 

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.36 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rabbit

Application Route: Subcutaneous

Fertility: NOAEL: 0.072 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 0.36 mg/kg body weight

Result: No effects on foetal development

Species: Rabbit

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0.072 mg/kg body weight

Result: Fetotoxicity

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

m-Cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Prenatal development toxicity study (teratogenicity)

Species: Rat

Application Route: Ingestion

Result: negative

## STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

#### Components:

#### Insulin Glargine:

Exposure routes : Ingestion

Target Organs : Blood, Nervous system

Assessment : May cause damage to organs through prolonged or repeated



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

exposure.

Repeated dose toxicity

Components:

Insulin Glargine:

Species: RatNOAEL: 0.5 mg/kgLOAEL: 1.5 mg/kgApplication Route: Subcutaneous

Exposure time : 30 d

Target Organs : Blood, Nervous system

m-Cresol:

Species : Rat
NOAEL : 150 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Method : OECD Test Guideline 408

**Aspiration toxicity** 

Not classified based on available information.

Experience with human exposure

**Components:** 

**Insulin Glargine:** 

Inhalation : Target Organs: Blood

Symptoms: Hypoglycemia, Headache, Sweating, Tremors,

nausea

**SECTION 12. ECOLOGICAL INFORMATION** 

**Ecotoxicity** 

**Components:** 

m-Cresol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 8.6 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia pulex (Water flea)): > 99.5 mg/l

Exposure time: 48 h

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 1.35 mg/l

Exposure time: 32 d

Remarks: Based on data from similar materials

Toxicity to daphnia and other : NOEC (Daphnia magna (Water flea)): 1 mg/l



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

aquatic invertebrates (Chron- Exposure time: 21 d

ic toxicity) Remarks: Based on data from similar materials

Persistence and degradability

**Components:** 

m-Cresol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 90 % Exposure time: 28 d

Method: OECD Test Guideline 301D

Bioaccumulative potential

**Components:** 

m-Cresol:

Bioaccumulation : Species: Leuciscus idus (Golden orfe)

Bioconcentration factor (BCF): 17 - 20

Partition coefficient: n-

octanol/water

log Pow: 1.96

Mobility in soil
No data available

Other adverse effects

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS** 

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION** 

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

**IATA-DGR** 

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen-

ger aircraft)

Not applicable

**IMDG-Code** 

Not applicable **UN** number Proper shipping name Not applicable Not applicable Class Not applicable Subsidiary risk Not applicable Packing group Labels Not applicable EmS Code Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

## **National Regulations**

**ADG** 

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

## **SECTION 15. REGULATORY INFORMATION**

# Safety, health and environmental regulations/legislation specific for the substance or mixture

Therapeutic Goods (Poisons :

Standard) Instrument

No poison schedule number allocated (Please use the original publication to check for specific uses, specific conditions or

threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applic

There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regula-

tions.



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16: ANY OTHER RELEVANT INFORMATION**

#### **Further information**

Revision Date : 06.04.2024

Sources of key data used to : Intern

compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

AU OEL : Australia. Workplace Exposure Standards for Airborne Con-

taminants.

ACGIH / TWA : 8-hour, time-weighted average

AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Trans-



## **Insulin Glargine Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.2 06.04.2024 42873-00026 Date of first issue: 07.01.2015

portation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN